At an industry conference, we spoke with Yann Péoc’h, World Operations Transformation Excellence Director at Servier, about how deep data from Veeva Link Key People is reshaping key opinion leader engagement across the product lifecycle.
Péoc’h emphasized that data driven KOL engagement has become critical as Servier prepares for multiple upcoming launches, particularly as the company expands into new therapeutic areas. He noted that understanding who to engage, how patient pathways evolve, and which stakeholders truly influence care decisions is foundational to meaningful engagement. Without this clarity, field teams risk relying on assumptions rather than evidence.
Discussing oncology launches, Péoc’h highlighted the complexity of country specific and even sub national care pathways. He explained that no single global framework can capture the nuances of local practice, making tailored, market level strategies essential. Access to robust KOL data enables teams to align launch preparation with the realities of each healthcare system.
Péoc’h also introduced Servier’s shift from subjective assessments of influence to measurable, scored indicators of reach and impact. This transition has allowed the company to validate long held beliefs about established leaders while also uncovering emerging voices, even in mature markets where relationships have existed for years.
Looking ahead, Péoc’h urged the industry to move beyond siloed data ownership and toward shared access across clinical, medical, commercial, and compliance teams. “The real transformation is not just having the data,” he said, “but changing how people actually use it before they engage.”
This content is sponsored by Veeva.
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
